Blood lipid lowering composition containing agarwood leaves and preparation method and use thereof

Abstract

The present application discloses a lipid-lowering composition containing agarwood leaves, a preparation method and a use thereof. The lipid-lowering composition comprises, by weight: 8-16 parts of agarwood leaves; 14-20 parts of astragalus; 12-18 parts of cassia seed; 7-15 parts of gynostemma pentaphyllum; and 10-14 parts of gardenia. The lipid-lowering composition provided by the present application can not only directly reduce cholesterol content, but also further improve the overall lipid-lowering effect (cholesterol concentration) by promoting gastrointestinal peristalsis.

Description

Technical Field

[0001] The present application relates to the technical field of blood lipid lowering drugs, and in particular to a blood lipid lowering composition containing agarwood leaves, and a preparation method and use thereof. Background Art

[0002] Blood lipids are the general term for lipids in plasma or serum, mainly cholesterol, triglycerides, phospholipids, free fatty acids, etc. When the lipid content in the blood exceeds the normal concentration, it is called hyperlipidemia. Since plasma lipids are fat-soluble substances, they combine with proteins in the blood to form water-soluble complexes that can circulate throughout the body, so it is also called hyperlipoproteinemia.

[0003] At present, the main lipid-lowering drugs in clinical practice are: statins, fibrates, niacin, bile acid chelators and unsaturated fatty acids, etc. However, these drugs have different degrees of gastrointestinal reactions, nausea, constipation or diarrhea, headache and dizziness, liver damage and other side effects.

[0004] Compared with Western medicine treatment, Chinese medicine not only has more ideal results in lowering blood lipids, but also generally has no side effects or only has relatively small side effects.

[0005] Therefore, researching and developing Chinese herbal medicines that assist in lowering blood lipids is of great significance for alleviating cardiovascular and cerebrovascular diseases caused by hyperlipidemia. Summary of the invention

[0006] The purpose of the present application is to provide a lipid-lowering composition containing agarwood leaves, and a preparation method and use thereof.

[0007] To achieve the above technical objectives, the present application provides the following technical solutions:

[0008] The first aspect of the embodiment of the present application provides a lipid-lowering composition containing agarwood leaves, and the lipid-lowering composition comprises, by weight:

[0009] 8-16 parts of agarwood leaves;

[0010] 14-20 parts of Astragalus;

[0011] 12-18 parts of Cassia seed;

[0012] Gynostemma pentaphyllum 7-15 parts;

[0013] 10-14 portions of Gardenia.

[0014] As an embodiment, the lipid-lowering composition comprises, by weight:

[0015] 10-14 parts agarwood leaves;

[0016] 15-18 parts of Astragalus;

[0017] 13-16 parts of Cassia seed;

[0018] Gynostemma pentaphyllum 10-13 parts;

[0019] 12-13 servings of Gardenia.

[0020] As an embodiment, the lipid-lowering composition further comprises, by weight:

[0021] 1-5 parts of perilla oil.

[0022] As an embodiment, the lipid-lowering composition comprises, by weight:

[0023] 3-5 parts of perilla oil.

[0024] The second aspect of the embodiment of the present application provides a method for preparing the lipid-lowering composition containing agarwood leaves as described in the first aspect, the preparation method comprising:

[0025] Weigh each component in proportion, extract the components except Gynostemma pentaphyllum with an extraction solvent, and dry to obtain a mixture;

[0026] extracting the mixture using a supercritical fluid to obtain an extract;

[0027] The Gynostemma pentaphyllum and the extract are dissolved and stirred evenly to obtain a blood lipid lowering composition.

[0028] As an embodiment, the extraction solvent is an ethanol solution; the extraction temperature is 80-90°C and the extraction time is 60-80 minutes.

[0029] As an embodiment, the supercritical fluid is carbon dioxide; the extraction temperature is 30-50°C, the pressure is 30-40MPa, and the time is 2-5h.

[0030] The third aspect of the embodiments of the present application provides the use of the lipid-lowering composition containing agarwood leaves as described in the first aspect in the preparation of a drug for preventing, alleviating or treating hyperlipidemia.

[0031] The embodiments of the present application have at least the following beneficial effects:

[0032] In the embodiments of the present application, Gynostemma pentaphyllum can improve blood lipid metabolism, can reduce total cholesterol, increase high-density lipoprotein cholesterol, reduce low-density lipoprotein cholesterol, and promote cholesterol esterification into the liver, thereby accelerating the removal of cholesterol in the blood and reducing blood lipids. After Gynostemma pentaphyllum promotes cholesterol esterification into the liver, the astragaloside provided by Astragalus membranaceus can work together with the active substances (such as flavonoids) in Aquilaria sinensis leaves to improve the activity of reducing blood lipids; and Cassia seed can provide rhein, emodin and anthraquinone substances to participate in reducing blood lipid content in the blood; at the same time, Cassia seed can promote gastrointestinal motility together with Aquilaria sinensis leaves, can further reduce cholesterol concentration, prevent deposition on blood vessel walls, and have a better auxiliary effect on reducing blood lipids. The fatty acids and linoleic acid contained in Gardenia jasminoides can dissolve cholesterol and promote gastrointestinal motility.

[0033] Therefore, the lipid-lowering composition provided in the embodiments of the present application can not only directly reduce the cholesterol content, but also further improve the overall lipid-lowering effect (cholesterol concentration) by promoting gastrointestinal motility.

[0034] Additional aspects and advantages of the present application will be partially given in the following description, which will become apparent from the following description, or will be understood through the practice of the present application. DETAILED DESCRIPTION

[0035] In order to more fully understand the technical content of the present application, the present application will be further introduced and illustrated in conjunction with specific embodiments below; obviously, the embodiments described below are only part of the embodiments of the present application, rather than all of the embodiments; based on the embodiments in the present application, all other embodiments obtained by those skilled in the art without making any creative work are within the scope of protection of the present application.

[0036] For those skilled in the art, the features, beneficial effects and advantages of the present application will become apparent by reading the contents disclosed in this specification.

[0037] The term "mass content" herein may be represented by the symbol "part(s)".

[0038] As used herein, "includes," "comprising," "including," "containing," "having," or other variations are intended to encompass non-closed inclusions, and no distinction is made between these terms. The term "comprising" means that other steps and ingredients that do not affect the end result may be added. The term "comprising" also includes the terms "consisting of" and "consisting essentially of." The compositions and methods / processes of the present application may include, consist of, and consist essentially of the essential elements and limitations described herein, as well as any additional or optional ingredients, components, steps, or limitations described herein.

[0039] In the present application, the specific sources of agarwood leaves, astragalus, cassia seed, gynostemma pentaphyllum, gardenia and perilla oil are not specifically limited. The above components can be purchased from the market or extracted or prepared by conventional methods known in the art.

[0040] Specifically:

[0041] The agarwood leaves in this embodiment are fresh agarwood leaves picked from Chenxiang Mountain, Guanzhu Town, Dianbai District, Maoming City;

[0042] Astragalus was purchased from Bozhou Junrantang Biotechnology Co., Ltd.;

[0043] Cassia seed was purchased from Bozhou Kuanshuntang Trading Co., Ltd.;

[0044] Gynostemma pentaphyllum extract was purchased from Shaanxi Hongze Bioengineering Co., Ltd., with the product number HZ-083;

[0045] Gardenia jasminoides was purchased from Hunan Gaoqiao Market Medicinal Materials Co., Ltd.;

[0046] Perilla oil was purchased from Xuchang Yuanhua Biotechnology Co., Ltd.

[0047] The lipid-lowering composition in the examples of the present application will be described in detail below.

[0048] Blood lipid lowering composition containing agarwood leaves

[0049] This embodiment provides a lipid-lowering composition containing agarwood leaves. Calculated by weight, the lipid-lowering composition includes: 8-16 parts of agarwood leaves; 14-20 parts of astragalus; 12-18 parts of cassia seeds; 7-15 parts of gynostemma pentaphyllum; and 10-14 parts of gardenia.

[0050] Those skilled in the art will know that agarwood leaves are rich in active substances (such as flavonoids). Flavonoids have the effect of promoting fat metabolism, reducing fat deposition in the body, and regulating gastrointestinal function, thereby having the effect of lowering blood lipids.

[0051] However, the inventors found during the experiment that the lipid-lowering effect of agarwood leaves was not obvious when used alone. In view of this, this embodiment further added astragalus, cassia seed, gynostemma pentaphyllum and gardenia to agarwood leaves. As a result, the lipid-lowering composition of this embodiment can significantly reduce the blood lipid content in the blood, regulate blood pressure, reduce serum cholesterol, and effectively prevent cardiovascular diseases such as atherosclerosis.

[0052] Specifically, in this embodiment: Gynostemma pentaphyllum can improve blood lipid metabolism, can reduce total cholesterol, increase high-density lipoprotein cholesterol, reduce low-density lipoprotein cholesterol, and promote cholesterol esterification into the liver, thereby accelerating the removal of cholesterol in the blood and reducing blood lipids. After Gynostemma pentaphyllum promotes cholesterol esterification into the liver, the astragaloside provided by Astragalus can work together with the active substances (such as flavonoids) in Aquilaria sinensis leaves to improve the activity of reducing blood lipids; while Cassia seed can provide rhein, emodin and anthraquinone substances to participate in reducing blood lipid content; at the same time, Cassia seed can promote gastrointestinal motility together with Aquilaria sinensis leaves, can further reduce cholesterol concentration, prevent deposition on blood vessel walls, and have a better auxiliary effect on reducing blood lipids. The fatty acids and linoleic acid contained in Gardenia jasminoides can dissolve cholesterol and promote gastrointestinal motility.

[0053] Therefore, the lipid-lowering composition provided in this embodiment can not only directly reduce the cholesterol content, but also further improve the overall lipid-lowering effect (cholesterol concentration) of the composition by promoting gastrointestinal motility.

[0054] As a preferred embodiment, the above-mentioned lipid-lowering composition comprises, by weight: 10-14 parts of agarwood leaves; 15-18 parts of astragalus; 13-16 parts of cassia seeds; 10-13 parts of gynostemma pentaphyllum; and 12-13 parts of gardenia.

[0055] For example, in this embodiment:

[0056] The content of agarwood leaves includes but is not limited to: 8 parts, 9 parts, 9.5 parts, 9.9 parts, 10 parts, 10.3 parts, 11 parts, 11.7 parts, 12 parts, 12.2 parts, 12.4 parts, 13 parts, 13.7 parts, 14 parts, 14.6 parts, 15 parts, 15.4 parts, and 16 parts.

[0057] The content of Astragalus includes but is not limited to: 14 parts, 14.5 parts, 14.9 parts, 15 parts, 15.5 parts, 15.6 parts, 16 parts, 16.2 parts, 16.6 parts, 17 parts, 17.5 parts, 17.8 parts, 18 parts, 18.4 parts, 19 parts, 19.5 parts, 19.6 parts, and 20 parts.

[0058] The content of Cassia seed includes but is not limited to: 12 parts, 12.2 parts, 12.4 parts, 13 parts, 13.7 parts, 14 parts, 14.5 parts, 14.9 parts, 15 parts, 15.5 parts, 15.6 parts, 16 parts, 16.2 parts, 16.6 parts, 17 parts, 17.5 parts, 17.8 parts, and 18 parts.

[0059] The content of Gynostemma pentaphyllum includes but is not limited to: 7 parts, 7.2 parts, 7.5 parts, 7.6 parts, 7.7 parts, 8 parts, 9 parts, 9.5 parts, 9.9 parts, 10 parts, 10.3 parts, 11 parts, 11.7 parts, 12 parts, 12.2 parts, 12.4 parts, 13 parts, 13.7 parts, 14 parts, 14.6 parts, and 15 parts.

[0060] The content of gardenia includes but is not limited to: 10 parts, 10.3 parts, 11 parts, 11.7 parts, 12 parts, 12.2 parts, 12.4 parts, 13 parts, 13.7 parts, and 14 parts.

[0061] Perilla oil

[0062] In addition to the above components, the lipid-lowering composition of this embodiment, as a preferred embodiment of this embodiment, further comprises: 1-5 parts of perilla oil, preferably 3-5 parts.

[0063] Among them, the inventors have found through verification that further adding perilla oil to the above lipid-lowering composition can achieve a better effect of lowering blood lipids. It is speculated that the principle may be:

[0064] In the lipid-lowering composition, the unsaturated fatty acids contained in perilla oil can combine with cholesterol in the human body together with gardenia and agarwood leaves, and promote metabolism, thereby further reducing the arterial deposits of cholesterol in the human body.

[0065] In this embodiment:

[0066] The content of perilla oil includes but is not limited to: 1 part, 1.5 parts, 1.9 parts, 2 parts, 2.3 parts, 2.5 parts, 2.7 parts, 3 parts, 3.2 parts, 3.4 parts, 4 parts, 4.7 parts, 4.9 parts, and 5 parts.

[0067] Preparation method

[0068] The preparation method of the above-mentioned lipid-lowering composition will be described in detail below. The preparation method comprises:

[0069] Weigh each component in proportion, extract the components except Gynostemma pentaphyllum with an extraction solvent, and dry to obtain a mixture;

[0070] extracting the mixture using a supercritical fluid to obtain an extract;

[0071] The Gynostemma pentaphyllum and the extract are dissolved and stirred evenly to obtain a blood lipid lowering composition.

[0072] Generally, when the lipid-lowering composition contains perilla oil and a pharmaceutically acceptable adjuvant, the perilla oil and other components are not subjected to extraction and extraction, but are directly mixed evenly with the extract.

[0073] In this embodiment, the Gynostemma pentaphyllum used is a Gynostemma pentaphyllum extract, and therefore, there is no need to extract the Gynostemma pentaphyllum. The Gynostemma pentaphyllum and the extract can be directly dissolved and stirred to obtain a lipid-lowering composition.

[0074] It should be understood that this embodiment does not specifically limit the source of Gynostemma pentaphyllum; when Gynostemma pentaphyllum is fresh Gynostemma pentaphyllum, the fresh Gynostemma pentaphyllum can be extracted together with other components to obtain an extract.

[0075] When the extract, perilla oil (if any) and pharmaceutically acceptable adjuvant (if any) are mixed, water is usually added, and the above substances are added to a homogenizer for mixing and homogenization; usually, the amount of water is 40-100 parts, preferably 50-90 parts. For example: 40 parts, 50 parts, 60 parts, 70 parts, 80 parts, 90 parts, 100 parts.

[0076] As an embodiment, the extraction solvent is an ethanol solution; the extraction temperature is 80-90°C and the extraction time is 60-80 minutes.

[0077] As an embodiment, the supercritical fluid is carbon dioxide; the extraction temperature is 30-50°C, the pressure is 30-40MPa, and the time is 2-5h.

[0078] Exemplarily, the ethanol solution is 70%-90% ethanol solution, preferably 90% ethanol solution; the extraction temperature is 80°C, the time is 65 minutes, the extraction temperature is 40°C, the pressure is 35 MPa, and the time is 3.5 hours.

[0079] Generally, before mixing the components with the extraction solvent, it is preferred to dry the components; the drying temperature is preferably 45-55°C, more preferably 50°C, and the drying time is preferably 15-30 min, more preferably 20 min.

[0080] During the extraction process, the solid-liquid ratio of each component to the ethanol solution is 1: (25-30) g / mL, preferably 1: 25 g / mL. Each component is preferably sieved through a 60-80 mesh sieve before extraction, preferably sieved through an 80 mesh sieve.

[0081] Specifically, the above preparation method is:

[0082] (1) Weigh each component in proportion, place each component in a 50°C oven to dry for 20 minutes, use a grinder to crush and pass through an 80-mesh sieve, add 90% ethanol solution to the crushed component, and the solid-liquid ratio is 1:25 g / mL; then place it in an 80°C water bath for extraction for 65 minutes, filter it with a circular filter paper, and reserve the filtrate; add ethanol to the filter residue again, repeat the extraction once according to the above conditions, and then filter it with a circular filter paper, combine the two extraction filtrates, place it in a constant temperature drying oven, and dry it at 50°C for 3.5 hours to obtain a mixture powder;

[0083] (2) In a supercritical extraction device, the mixture powder is extracted using a carbon dioxide supercritical fluid at an extraction temperature of 40° C. and a pressure of 35 MPa. The flow rate of the supercritical carbon dioxide fluid is set to 300 L / h. After 3.5 hours of extraction, an extract is obtained;

[0084] (3) The extract, perilla oil (if any), a pharmaceutically acceptable adjuvant (if any) and water are added to a homogenizer and mixed and homogenized (the first-stage pressure is 20 MPa and the second-stage pressure is 8 MPa) to obtain a lipid-lowering composition.

[0085] It is understandable that those skilled in the art can prepare the lipid-lowering composition into conventional dosage forms such as oral liquid, powder, ointment, etc. according to conventional means, and this embodiment does not limit this.

[0086] use

[0087] Since the lipid-lowering composition of this embodiment can effectively reduce blood lipids, the lipid-lowering composition provided in this embodiment can be used to prepare a drug for preventing, alleviating or treating hyperlipidemia.

[0088] That is, the lipid-lowering composition of this embodiment can be used as a basis, and pharmaceutically acceptable adjuvants can be added to prepare a drug for preventing, alleviating or treating hyperlipidemia.

[0089] Exemplarily, the drug is in the form of tablets, decoctions, powders, pills or granules.

[0090] Adjuvants

[0091] It should be understood that the pharmaceutically acceptable excipient used in this embodiment refers to a non-toxic carrier, adjuvant or vehicle that does not destroy the pharmacological activity of the lipid-lowering composition formulated together.

[0092] Pharmaceutically acceptable carriers, adjuvants or vehicles that can be used in the composition of the present invention include (but are not limited to) wetting agents, binders or disintegrants. The types and amounts of the above-mentioned wetting agents, binders or disintegrants should comply with the relevant provisions of the Chinese Pharmacopoeia.

[0093] For example, the disintegrant can be selected from one or more of sodium carboxymethylcellulose CMC, CMC-Na, and HPM.

[0094] It should be understood that the above-mentioned adjuvants may be selected in combination with the specific dosage form of the drug.

[0095] Drug administration

[0096] The lipid-lowering composition or drug provided in this embodiment can be administered by many routes, including but not limited to: oral administration, parenteral administration, inhalation administration, topical administration or other administration methods. For example, the lipid-lowering composition or drug used herein is a drug for oral administration or an injectable solution.

[0097] The present application is further described below in conjunction with the examples. It should be understood that these examples are only used to illustrate the present application and are not used to limit the scope of the present application.

[0098] In the following examples, the materials, reagents and instruments used can be purchased from commercial sources unless otherwise specified.

[0099] Examples 1-7

[0100] Examples 1-7 respectively provide blood lipid lowering compositions with the components shown in Table 1, and each component in the blood lipid lowering composition is measured by weight.

[0101] Table 1: Composition of the lipid-lowering composition of Examples 1-7 (parts by weight)

[0102] Components Example 1 Example 2 Example 3 Example 4 Example 5 Example 6 Example 7 Agarwood Leaves 8 10 14 16 14 14 14 Astragalus 20 18 15 14 15 15 15 Cassia seed 18 16 13 12 13 13 13 Gynostemma pentaphyllum 7 10 13 15 13 13 13 Gardenia 14 13 12 10 12 12 12 Perilla oil - - - - 1 3 5 water 60 60 60 60 60 60 60

[0103] Comparative Example 1-Comparative Example 5

[0104] Comparative Examples 1-5 respectively provide blood lipid lowering compositions with the components shown in Table 2, and each component in the blood lipid lowering composition is measured by weight.

[0105] Table 2: Composition of the lipid-lowering composition of Comparative Examples 1-5 (parts by weight)

[0106] Components Comparative Example 1 Comparative Example 2 Comparative Example 3 Comparative Example 4 Comparative Example 5 Agarwood Leaves - 14 14 14 14 Astragalus 15 - 15 15 15 Cassia seed 13 13 - 13 13 Gynostemma pentaphyllum 13 13 13 - 13 Gardenia 12 12 12 12 - water 60 60 60 60 60

[0107] The preparation method of the lipid-lowering composition of Examples 1-7 and Comparative Examples 1-5 comprises the following steps:

[0108] (1) Weigh each component in proportion, dry each component (except Gynostemma pentaphyllum and Perilla oil) in a 50°C oven for 20 minutes, crush it with a grinder and pass it through an 80-mesh sieve, add 90% ethanol solution to the crushed component, and the solid-liquid ratio is 1:25 g / mL; then extract it in an 80°C water bath for 65 minutes, filter it with a circular filter paper, and set aside the filtrate; add ethanol to the filter residue again, repeat the extraction once according to the above conditions, and then filter it with a circular filter paper, combine the two extraction filtrates, put it in a constant temperature drying oven, and dry it at 50°C for 3.5 hours to obtain a mixture powder;

[0109] (2) In a supercritical extraction device, the mixture powder is extracted using a carbon dioxide supercritical fluid at an extraction temperature of 40° C. and a pressure of 35 MPa. The flow rate of the supercritical carbon dioxide fluid is set to 300 L / h. After 3.5 hours of extraction, an extract is obtained;

[0110] (3) The extract, Gynostemma pentaphyllum, Perilla oil (if any) and water are added into a homogenizer and mixed and homogenized (the first-stage pressure is 20 MPa and the second-stage pressure is 8 MPa) to obtain a lipid-lowering composition.

[0111] Effect verification

[0112] The lipid-lowering composition prepared above was subjected to a lipid-lowering test.

[0113] Lipid-lowering test

[0114] The experimental animals were SD rats, half male and half female, a total of 84 SD rats, which were purchased from Jiangsu Huachuang Xinnuo Pharmaceutical Technology Co., Ltd.

[0115] After one week of adaptive feeding in the animal room, 84 rats were divided into a normal group (6 rats) and an experimental group (78 rats);

[0116] The normal group was fed with ordinary feed, while the experimental group was fed with high-fat feed. The composition of ordinary feed, calculated by mass percentage, was: 20% flour, 22% cornmeal, 13% sorghum flour, 22% bean cake, 11% wheat bran, 8% fish meal, 2% bone meal, and 2% salt. The composition of high-fat feed, calculated by mass percentage, was: 63% of the above ordinary feed, 17% lard, 10% cholesterol, and 10% sucrose.

[0117] The rats in each group were allowed to drink water and eat freely. After 4 weeks of feeding, the rats were weighed and the experimental group was made into a high-fat model group. 78 rats in the high-fat model group were randomly divided into 13 groups, including the high-fat model group, Example 1-7 groups, and Comparative Example 1-5 groups, with 6 rats in each group.

[0118] The lipid-lowering composition prepared in the corresponding group was administered (gavage) to the Example 1-7 group and the Comparative Example 1-5 group. The lipid-lowering composition was dissolved and dispersed in water, and the dosage was calculated according to the crude drug amount of 12g / kg; the hyperlipidemia model group and the normal group were respectively given the same dose of normal saline. After continuous gavage for 20 days, fasting but not water for 12h; serum was taken and the levels of total cholesterol (TC) and total triglyceride (TG) in serum were determined by a fully automatic biochemical analyzer. The test results are shown in Table 3.

[0119] Table 3: Results of lipid-lowering test

[0120] Group TC content (mmol / L) TG content (mmol / L) Normal group 1.68±0.43 1.35±0.29 High-fat control group <![CDATA[8.65±0.59 * ]]> <![CDATA[2.85±0.42 * ]]> Example 1 <![CDATA[3.35±0.45 # ]]> <![CDATA[1.83±0.31 # ]]> Example 2 <![CDATA[3.22±0.63 # ]]> <![CDATA[1.72±0.27 # ]]> Example 3 <![CDATA[3.18±0.41 # ]]> <![CDATA[1.66±0.35 # ]]> Example 4 <![CDATA[3.28±0.47 # ]]> <![CDATA[1.76±0.28 # ]]> Example 5 <![CDATA[2.71±0.52 # ]]> <![CDATA[1.46±0.32 # ]]> Example 6 <![CDATA[2.61±0.33 # ]]> <![CDATA[1.39±0.22 # ]]> Example 7 <![CDATA[2.65±0.45 # ]]> <![CDATA[1.42±0.37 # ]]> Comparative Example 1 <![CDATA[5.18±0.62 #△ ]]> <![CDATA[2.16±0.29 #△ ]]> Comparative Example 2 <![CDATA[4.65±0.48 #△ ]]> <![CDATA[2.04±0.41 #△ ]]> Comparative Example 3 <![CDATA[5.12±0.32 #△ ]]> <![CDATA[2.11±0.34 #△ ]]> Comparative Example 4 <![CDATA[5.27±0.52 #△ ]]> <![CDATA[2.25±0.35 #△ ]]> Comparative Example 5 <![CDATA[5.14±0.57 #△ ]]> <![CDATA[2.14±0.72 #△ ]]>

[0121] Note: In the above table, * indicates that the comparison with the normal group is statistically significant, *P < 0.05; # indicates that the comparison with the high-fat model group is statistically significant, #P < 0.05; △ indicates that the comparison with the Example 3 group is statistically significant, △P < 0.05.

[0122] According to the test results in Table 3, by comparing the high-fat model group with the normal group, it can be seen that after the model rats were fed with high-fat for 4 weeks, their blood lipid index was significantly higher than that of the normal group, with significant statistical differences (*P<0.05), indicating that the model was successfully established.

[0123] Combined with the test results in Table 3, the lipid-lowering compositions prepared in Examples 1-5 using agarwood leaves, astragalus, cassia seed, gynostemma pentaphyllum and gardenia have significantly decreased total cholesterol and total triglycerides in rats; indicating that the lipid-lowering compositions of Examples 1-5 can significantly reduce the blood lipid content, reduce serum cholesterol, and effectively prevent cardiovascular diseases such as atherosclerosis.

[0124] Specifically, Example 5-7 further added perilla oil on the basis of Example 3. Compared with Example 3, the levels of total cholesterol and total triglycerides in rats in Example 5-7 were further significantly reduced, indicating that this example further added perilla oil on the basis of the above-mentioned lipid-lowering composition, which can better achieve the effect of lowering blood lipids.

[0125] It should be understood that in the lipid-lowering composition, the unsaturated fatty acids contained in perilla oil can combine with cholesterol in the human body together with gardenia and agarwood leaves and promote metabolism, thereby further reducing the arterial deposits of cholesterol in the human body.

[0126] Further comparing Example 3 with Comparative Examples 1-5, when Comparative Examples 1-5 lacked one of Aquilaria sinensis leaves, Astragalus, Cassia seed, Gynostemma pentaphyllum or Gardenia jasminoides, the reduction levels of total cholesterol and total triglycerides in rats were significantly lower than those in Example 3, indicating that in this embodiment, Aquilaria sinensis leaves, Astragalus, Cassia seed, Gynostemma pentaphyllum and Gardenia jasminoides can work together to better reduce the cholesterol content, thereby improving the lipid-lowering effect of the lipid-lowering composition.

[0127] Among them, in the absence of agarwood leaves, cassia seeds or gardenia, the reduction levels of total cholesterol and total triglycerides in Comparative Examples 1, 3 and 5 are not as good as those in Comparative Example 2 (the lipid-lowering effect is worse), indicating that agarwood leaves, cassia seeds and gardenia can not only reduce cholesterol content through their own active substances, but also better promote gastrointestinal motility, thereby further improving the lipid-lowering effect of the lipid-lowering composition.

[0128] In contrast, when Gynostemma pentaphyllum was absent, the decrease levels of total cholesterol and total triglycerides in Comparative Example 4 were not as good as those in Comparative Examples 1-3 and Comparative Example 5 (the lipid-lowering effect was worse), indicating that Gynostemma pentaphyllum had the greatest effect on the change in cholesterol content in this embodiment. This may be because Gynostemma pentaphyllum can improve blood lipid metabolism, while lowering total cholesterol, increasing high-density lipoprotein cholesterol, and lowering low-density lipoprotein cholesterol, it can also promote cholesterol esterification and enter the liver, thereby accelerating the removal of cholesterol in the blood and lowering blood lipids.

[0129] In summary, this embodiment adopts the above components, among which Gynostemma pentaphyllum can improve blood lipid metabolism, can reduce total cholesterol, increase high-density lipoprotein cholesterol, reduce low-density lipoprotein cholesterol, and promote cholesterol esterification into the liver, thereby accelerating the removal of cholesterol in the blood and reducing blood lipids. After Gynostemma pentaphyllum promotes cholesterol esterification into the liver, the astragaloside provided by Astragalus membranaceus can work together with the active substances (such as flavonoids) in Aquilaria sinensis leaves to improve the activity of lowering blood lipids; and Cassia seed can provide rhein, emodin and anthraquinone substances to participate in reducing blood lipid content in the blood; at the same time, Cassia seed can promote gastrointestinal motility together with Aquilaria sinensis leaves, can further reduce cholesterol concentration, prevent deposition on blood vessel walls, and have a better auxiliary effect on lowering blood lipids. The fatty acids and linoleic acid contained in Gardenia jasminoides can dissolve cholesterol and promote gastrointestinal motility.

[0130] Therefore, the lipid-lowering composition provided in this embodiment can not only directly reduce the cholesterol content, but also further improve the overall lipid-lowering effect (cholesterol concentration) by promoting gastrointestinal motility.

[0131] The technical solution provided by the present application is introduced in detail above. Specific examples are used in this article to illustrate the principles and implementation methods of the present application. The description of the above embodiments is only applicable to help understand the principles of the present application. At the same time, for general technical personnel in this field, according to the present application, there will be changes in the specific implementation methods and application scope. In summary, the content of this specification should not be understood as a limitation on the present application.

Claims

1. A lipid-lowering composition containing agarwood leaves, characterized in that: The lipid-lowering composition is prepared from the following raw materials by weight: 8-16 parts of agarwood leaves; 14-20 parts of Astragalus; 12-18 parts of Cassia seed; Gynostemma pentaphyllum 7-15 parts; 10-14 portions of Gardenia.

2. The lipid-lowering composition containing agarwood leaves according to claim 1, characterized in that: The lipid-lowering composition comprises, by weight: 10-14 parts agarwood leaves; 15-18 parts of Astragalus; 13-16 parts of Cassia seed; Gynostemma pentaphyllum 10-13 parts; 12-13 servings of Gardenia.

3. A method for preparing the lipid-lowering composition containing agarwood leaves according to any one of claims 1 to 2, characterized in that: The preparation method comprises: Weigh each component in proportion, extract the components except Gynostemma pentaphyllum with an extraction solvent, and dry to obtain a mixture; extracting the mixture using a supercritical fluid to obtain an extract; The extract and Gynostemma pentaphyllum are dissolved and stirred evenly to obtain a blood lipid lowering composition.

4. The preparation method according to claim 3, characterized in that: The extraction solvent is ethanol solution; the extraction temperature is 80-90° C. and the extraction time is 60-80 min.

5. The preparation method according to claim 3, characterized in that: The supercritical fluid is carbon dioxide; the extraction temperature is 30-50°C, the pressure is 30-40MPa, and the extraction time is 2-5h.

6. Use of the lipid-lowering composition containing agarwood leaves according to any one of claims 1 to 2 in the preparation of a medicament for preventing, alleviating or treating hyperlipidemia.